Compare KALV & RNP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KALV | RNP |
|---|---|---|
| Founded | N/A | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2014 | N/A |
| Metric | KALV | RNP |
|---|---|---|
| Price | $26.74 | $20.47 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $32.60 | N/A |
| AVG Volume (30 Days) | ★ 4.5M | 78.0K |
| Earning Date | 07-09-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.94% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $50,000,000.00 | N/A |
| Revenue This Year | $185.42 | N/A |
| Revenue Next Year | $59.23 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 495.66 | N/A |
| 52 Week Low | $9.83 | $19.27 |
| 52 Week High | $26.85 | $22.99 |
| Indicator | KALV | RNP |
|---|---|---|
| Relative Strength Index (RSI) | 74.83 | 40.03 |
| Support Level | $14.56 | $19.90 |
| Resistance Level | N/A | $20.55 |
| Average True Range (ATR) | 0.15 | 0.26 |
| MACD | 0.01 | -0.06 |
| Stochastic Oscillator | 98.60 | 1.49 |
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
Cohen & Steers REIT and Preferred Income Fund Inc is a diversified, closed-ended investment management fund. Its investment objective is to provide high current income with capital appreciation as its secondary objective. The Fund invests at least its total assets in common stocks issued by real estate investment trusts (REITs) and preferred securities under normal circumstances. The Fund seeks to achieve its objectives through a portfolio of income producing common stock issued by REITs and preferred and other debt securities.